Volume 6.37 | Sept 25

Mammary Cell News 6.37 September 25, 2014
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  MCN on Twitter
​ΔNp63 Promotes Stem Cell Activity in Mammary Gland Development and Basal-Like Breast Cancer by Enhancing ​Fzd7 Expression and Wnt Signaling
Researchers show that the ​ΔNp63 isoform of the ​Trp63 transcription factor promotes normal mammary stem cell activity by increasing the expression of the Wnt receptor ​Fzd7, thereby enhancing Wnt signaling. [Nat Cell Biol] Abstract
Learn More: Column-Free Enrichment of Mouse Mammary Stem & Progenitor Cells
PUBLICATIONS (Ranked by impact factor of the journal)

A Breast Cancer Stem Cell-Selective, Mammospheres-Potent Osmium(VI) Nitrido Complex
Scientists report the effect of a newly developed osmium(VI) nitrido complex on breast cancer stem cells (CSCs). The osmium complex displays selective toxicity for HMLER breast cancer cells enriched with CD44-positive, CSC-like cells compared to the same cells having reduced CSC character. [J Am Chem Soc] Abstract

BRCA1 Suppresses Epithelial-to-Mesenchymal Transition and Stem Cell Dedifferentiation during Mammary and Tumor Development
Investigators demonstrate that disrupting BRCA1 by either germline or epithelium-specific mutation in p18-deficient mice activates epithelial-to-mesenchymal transition and induces dedifferentiation of luminal stem cells, which associate closely with expansion of basal and cancer stem cells and formation of basal-like tumors. [Cancer Res] Abstract

Progesterone Downregulation of miR-141 Contributes to Expansion of Stem-Like Breast Cancer Cells through Maintenance of Progesterone Receptor and Stat5a
Researchers investigated progesterone downregulation of miR-141, a member of the miR-200 family of tumor suppressors, in facilitating an increase in stem-like breast cancer cells. [Oncogene] Abstract

miR-143 and miR-145 Synergistically Regulate ERBB3 to Suppress Cell Proliferation and Invasion in Breast Cancer
ERBB3, one of the four members of the ErbB family of receptor tyrosine kinases, plays an important role in breast cancer etiology and progression. Scientists identified novel miRNAs that can potentially target ERBB3 and their biological functions. [Mol Cancer] Abstract | Full Article

Identification of MicroRNA-93 as a Functional Dysregulated miRNA in Triple-Negative Breast Cancer
The miR-93 expression level in triple-negative breast cancer tissues was significantly higher than that in non-triple-negative breast cancer tissues. The potentials of proliferation, invasion, and metastasis in breast cancer MCF-7 cells were promoted by ectopic transfection of miR-93. [Tumor Biol] Abstract

Inhibition of p300 Suppresses Growth of Breast Cancer: Role of p300 Subcellular Localization
The authors investigated the role p300 has on breast cancer by performing pharmacological inhibition of p300 acetyl-transferase function and analyzing the effects on cell count, migration and invasion in LM3 murine breast cancer cell line and on tumor progression in a syngeneic murine model. [Exp Mol Pathol] Abstract

The Crosstalk between Dectin1 and TLR4 via NF-κB Subunits p65/RelB in Mammary Epithelial Cells
Researchers demonstrate that β-glucan up-regulates Dectin1 and LPS up-regulates TLR4 directly, as confirmed by generation of siDectin1 and siTLR4 in rat mammary epithelial cells. [Int Immunopharmacol] Abstract

Population Pharmacokinetics of Artesunate and Dihydroartemisinin during Long-Term Oral Administration of Artesunate to Patients with Metastatic Breast Cancer
Investigators characterized the population pharmacokinetics of artesunate (ARS) and its active metabolite dihydroartemisinin (DHA) in patients with metastatic breast cancer during long-term (>3 weeks) daily oral ARS administration and studied the relationship between salivary and plasma concentrations of DHA. [Eur J Clin Pharmacol] Abstract

Tunicamycin-Induced ER Stress Regulates Chemokine CCL5 Expression and Secretion via STAT3 Followed by Decreased Transmigration of MCF-7 Breast Cancer Cells
Scientists investigated the role of endoplasmic reticulum (ER) stress in regulating chemokine C-C motif ligand 5 (CCL5) expression and its relationship with signal transducer and activator of transcription 3 (STAT3). Also, the effect of tunicamycin, a classical ER stress inducer, and CCL5 on the transmigration of human breast cancer MCF-7 cells was observed and analyzed. [Oncol Rep] Abstract


Antiandrogen Therapy in Metastatic Male Breast Cancer: Results from an Updated Analysis in an Expanded Case Series
As the androgen receptor is emerging as a potential oncogenic driver in male breast cancer, researchers analyzed efficacy data from metastatic patients treated with antiandrogens.They evaluated the activity of cyproterone acetate, either as a monotherapy or combined with a GnRH analog, in 36 metastatic male breast cancer patients. [Breast Cancer Res Treat] Abstract

Phase I Combination Study of Eribulin Mesylate with Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
Scientists studied eribulin mesylate in combination with trastuzumab to evaluate dose limiting toxicity, tolerability/safety, pharmacokinetics, and efficacy and estimated the recommended dose in Japanese patients with advanced or recurrent HER2+ breast cancer. [Invest New Drugs] Abstract | Full Article

[Alt-text] Free Interactive Tutorial: Explore Mammary Progenitor Cell Colonies
Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport – An Update
The authors provide an update of current knowledge on basic biochemistry and pharmacological functions of human breast cancer resistance protein as well as its relevance to drug resistance and drug disposition.

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
NuView Life Sciences Enters Global Licensing Agreement with Otsuka Pharmaceutical
NuView Life Sciences, Inc. announced entry into an exclusive global licensing and collaboration agreement with Otsuka Pharmaceutical Co., Ltd. to further develop and commercialize NuView’s investigative genomic-based diagnostic biomarker to detect cancers of the breast and prostate. [NuView Life Sciences, Inc. (PR Newswire Association LLC)]
Press Release

BioTime, Inc.’s Subsidiary OncoCyte Corporation and Abcodia to Collaborate on Breast Cancer Diagnostic Development
OncoCyte Corporation, a subsidiary of BioTime, Inc. and Abcodia Ltd. announced their collaboration focused on the development of OncoCyte’s blood-based PanC-Dx™ test for early detection of breast cancer. [BioTime, Inc.] Press Release

From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW XXII Congress of the European Society of Gene and Cell Therapy (ESGCT)
October 22-23, 2014
The Hague, The Netherlands

NEW CellTech India 2015
March 2-3, 2015
Bangalore, India

Visit our events page to see a complete list of events in the mammary cell community.
NEW Postdoctoral Research Fellow – Cell Cycle Regulatory Pathways in Breast Cancer (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Breast Cancer Research (The University of Texas MD Anderson Cancer Center)

Postdoctoral Position – Breast Cancer Research (Weizmann Institute of Science)

Postdoctoral Fellow – Stem Cells and Breast Cancer (Albert Einstein College of Medicine)

PhD Position – Breast Cancer Research (University of Iceland Biomedical Center)

Postdoctoral Positions – Cell Death of Normal Tissue Stem Cells (Sloan-Kettering Institute)

Postdoctoral Fellow – Breast Cancer Translational Research (University of Houston – College of Pharmacy)

Postdoctoral Fellow – Breast Cancer Research (Albert Einstein College of Medicine)

Scientist – Mammary Cell Research (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mammary Cell News: Archives | Events | Contact Us